81 results
Page 2 of 5
8-K
wo2fp0py 9k
12 Nov 21
Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS
6:30am
8-K
EX-99.1
iur provxe
12 Nov 21
Adaptimmune Reports Positive Results from its Pivotal SPEARHEAD-1 Trial in Patients with Synovial Sarcoma and MRCLS at CTOS
6:30am
8-K
EX-99.1
qrz3cj3gg 0c61f
4 Nov 21
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:40am
8-K
EX-99.1
55zf7 t9ir142r6ozn
13 Sep 21
Other Events
7:08am
8-K
7dmbyc
13 Sep 21
Other Events
7:08am
8-K
EX-99.1
oxuwios26s19mfvnnd
9 Aug 21
Adaptimmune Reports Second Quarter Financial Results and Business Update
4:08pm
8-K
EX-99.1
o9ifoe4bcx52gqhi
19 May 21
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
5:08pm
8-K
fvkj4hhmm2q
19 May 21
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
5:08pm
8-K
EX-99.1
kyt9grba2ocqj9
6 May 21
Adaptimmune Reports First Quarter Financial Results and Business Update
7:38am
8-K
EX-99.1
eah q98c2djkm6zqr
25 Feb 21
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
7:37am
8-K
EX-99.1
hjxfey95lijn0ap
20 Nov 20
Regulation FD Disclosure
7:36am
8-K
potzrf9rn
19 Nov 20
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
9:09am
8-K
EX-99.1
ihavep9 1wczhx4mbx
19 Nov 20
Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS
9:09am
8-K
EX-99.1
4lf5ki yvafeb56eq7
9 Nov 20
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
5:11pm